Key result
Telmisartan 80 mg resulted in a significantly lower incidence of cough (15.6%) compared to lisinopril 20 mg (60%), with rates comparable to placebo (9.7%).
Why the study?
Does telmisartan reduce the incidence of cough compared to lisinopril in patients with mild to moderate hypertension and prior ACE inhibitor-related cough?
Population
88 patients with mild to moderate hypertension who previously demonstrated ACE inhibitor-related cough
Comparison
Telmisartan 80 mg once daily vs Lisinopril 20 mg once daily or placebo once daily
Design
RCT, randomised, parallel-group, double-blind
Follow-up
8 weeks
Authors
Loading...
Telmisartan preferable to lisinopril for prior ACEI cough; confirms ARBs' tolerability edge in ACEI-intolerant hypertension.
RCT (n=88)
double-blind
parallel-group
Yes
Does telmisartan reduce the incidence of cough compared to lisinopril in patients with mild to moderate hypertension and prior ACE inhibitor-related cough?
Absolute Event Rate: 15.6% vs 60%
Telmisartan has a significantly lower incidence of cough compared to lisinopril, and comparable to placebo, in hypertensive patients with prior ACE inhibitor-related cough.
Yves Lacourcière (1999) conducted an RCT in mild to moderate hypertension (n=88). Telmisartan vs. Lisinopril 20 mg or placebo once daily was evaluated on Cough incidence. Telmisartan 80 mg resulted in a significantly lower incidence of cough (15.6%) compared to lisinopril 20 mg (60%), with rates comparable to placebo (9.7%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: